LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

Status Recruiting

Clinical Trial Summary

This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To evaluate the safety of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) (bio-IMPT) for pediatric patients with ependymoma. SECONDARY OBJECTIVES: I. To utilize advanced multiparametric magnetic resonance (MR) imaging to identify imaging biomarkers of structural and biological changes after proton therapy in pediatric ependymoma patients. II. To compare quantitative image biomarkers in patients treated with bio-IMPT and standard proton therapy using a voxel level analysis. III. To test and evaluate the validity of relative biological effectiveness (RBE) models and enhance their precision based on prospectively collected clinical image biomarkers. IV. To evaluate acute and late toxicities, including pseudoprogression and symptom burden, in patients treated with bio-IMPT. V. To estimate progression-free survival (PFS) and overall survival (OS). VI. To evaluate disease outcomes following the use of a simultaneous integrated boost (SIB) for pediatric ependymoma patients with gross residual disease following surgery. OUTLINE: Patients receive LET optimized IMPT for up to 6 weeks. After completion of study treatment, patients are followed up at 1 month, then every 3 months for up to 24 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03750513
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact	David Grosshans
Phone	713-563-2300
Email	dgrossha@mdanderson.org
Status	Recruiting
Phase	Phase 1
Start date	April 1, 2019
Completion date	December 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00994071` - A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	Phase 1
Completed	`NCT01171469` - Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor	Phase 1
Completed	`NCT00520936` - A Study of Pemetrexed in Children With Recurrent Cancer	Phase 2
Recruiting	`NCT04541082` - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms	Phase 1
Completed	`NCT02502708` - Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors	Phase 1
Recruiting	`NCT04049669` - Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG	Phase 2
Recruiting	`NCT06038760` - Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Active, not recruiting	`NCT03220035` - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT03194906` - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors	Phase 2
Completed	`NCT03043391` - Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	Phase 1
Active, not recruiting	`NCT03095248` - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors	Phase 2
Active, not recruiting	`NCT02125786` - A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma	Phase 2
Active, not recruiting	`NCT01096368` - Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma	Phase 3
Terminated	`NCT01247922` - Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205	Phase 2
Completed	`NCT03900689` - Social Determinants of Health in Glioblastoma Population
Recruiting	`NCT04661384` - Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma	Phase 1
Active, not recruiting	`NCT03434262` - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	Phase 1
Recruiting	`NCT05259605` - Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Terminated	`NCT01836549` - Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors	Phase 2
Active, not recruiting	`NCT03638167` - EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	Phase 1